Literature DB >> 10703939

Platelet-osteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1.

C Voland1, C M Serre, P Delmas, P Clézardin.   

Abstract

Approximately 20% of patients with osteosarcoma have metastatic disease in lungs or bones at diagnosis. The requirement of platelets in hematogenous dissemination of metastatic cells is now well established. Tumor cells interact with platelets and induce platelet aggregation. In this respect, metastatic potential of tumor cells correlates with their capacity to aggregate platelets in vitro. We have previously shown that thrombospondin 1 (TSP-1) is synthesized and expressed on the surface of MG-63 osteosarcoma cells and mediates platelet-osteosarcoma cell interaction. However, active sites mimicking the function of TSP-1 during platelet-osteosarcoma cell interaction are not known. In this study, a panel of antibodies directed against the N-terminal and C-terminal domains and type 1, type 2, and type 3 repeats of TSP-1 were first used to delineate the structural requirement for the binding of osteosarcoma cell surface-associated TSP-1 to platelets. A drastic inhibition of the platelet-aggregating activity of MG-63 cells was obtained in the presence of a monoclonal antibody directed against the N-terminal domain of TSP-1. Among a series of 16 synthetic peptides spanning the whole N-terminal domain of TSP-1, only synthetic peptide N12/I encompassing amino acid residues 151-164 of the N-terminal domain of TSP-1 inhibited the platelet-aggregating activity of MG-63 cells. Electron microscopy studies showed that peptide N12/I strongly inhibited platelet-osteosarcoma cell interaction. A polyclonal antibody directed against peptide N12/I specifically bound to the surface of MG-63 cells, recognized TSP-1 and drastically inhibited the platelet-aggregating activity of MG-63 cells. In addition, peptide N12/I specifically bound to fibrinogen and inhibited TSP-1/fibrinogen interaction. Overall, our results provide evidence that a fibrinogen-binding sequence located within the N-terminal domain of TSP-1 mediates the binding of osteosarcoma cell surface-associated TSP-1 to platelet-bound fibrinogen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10703939     DOI: 10.1359/jbmr.2000.15.2.361

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  7 in total

1.  The evolution of thrombospondins and their ligand-binding activities.

Authors:  Amber A Bentley; Josephine C Adams
Journal:  Mol Biol Evol       Date:  2010-04-28       Impact factor: 16.240

Review 2.  The thrombospondins.

Authors:  Josephine C Adams; Jack Lawler
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-10-01       Impact factor: 10.005

3.  The structures of the thrombospondin-1 N-terminal domain and its complex with a synthetic pentameric heparin.

Authors:  Kemin Tan; Mark Duquette; Jin-Huan Liu; Rongguang Zhang; Andrzej Joachimiak; Jia-huai Wang; Jack Lawler
Journal:  Structure       Date:  2006-01       Impact factor: 5.006

4.  Heparin-induced cis- and trans-dimerization modes of the thrombospondin-1 N-terminal domain.

Authors:  Kemin Tan; Mark Duquette; Jin-Huan Liu; Kumaran Shanmugasundaram; Andrzej Joachimiak; John T Gallagher; Alan C Rigby; Jia-huai Wang; Jack Lawler
Journal:  J Biol Chem       Date:  2007-12-07       Impact factor: 5.157

5.  Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis.

Authors:  Satoshi Takagi; Ai Takemoto; Miho Takami; Tomoko Oh-Hara; Naoya Fujita
Journal:  Cancer Sci       Date:  2014-07-28       Impact factor: 6.716

6.  Novel circulating peptide biomarkers for esophageal squamous cell carcinoma revealed by a magnetic bead-based MALDI-TOFMS assay.

Authors:  Kun Jia; Wei Li; Feng Wang; Haixia Qu; Yuanyuan Qiao; Lanping Zhou; Yulin Sun; Qingwei Ma; Xiaohang Zhao
Journal:  Oncotarget       Date:  2016-04-26

Review 7.  Fibrin as a Multipurpose Physiological Platform for Bone Tissue Engineering and Targeted Delivery of Bioactive Compounds.

Authors:  Bruno Bujoli; Jean-Claude Scimeca; Elise Verron
Journal:  Pharmaceutics       Date:  2019-10-28       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.